Welcome to our dedicated page for Alexion Pharms news (Ticker: ALXN), a resource for investors and traders seeking the latest updates and insights on Alexion Pharms stock.
Alexion Pharmaceuticals, Inc. (ALXN) generates frequent news flow related to rare diseases, complement inhibition and ultra-rare metabolic disorders. As a global biopharmaceutical company focused on the discovery, development and commercialization of medicines for devastating conditions, Alexion regularly reports clinical data, regulatory milestones and corporate developments that are relevant to investors, clinicians and patients.
News about Alexion often highlights results from clinical trials of its complement inhibitors in diseases such as paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS) and generalized myasthenia gravis (gMG). The company has announced Phase 3 data showing statistically significant improvements in patient-reported and physician-assessed outcomes in gMG, as well as long-term safety and efficacy findings in PNH. Updates from major scientific meetings, including the European Hematology Association Congress and the American Academy of Neurology annual meeting, provide additional detail on how these therapies perform in both clinical trial and real-world settings.
Alexion’s news flow also covers enzyme replacement therapies for hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D), and the use of a Factor Xa inhibitor reversal agent in acute care. Pipeline updates describe progress on mid-to-late-stage programs such as a copper-binding agent for Wilson disease, an anti-neonatal Fc receptor (FcRn) antibody for rare Immunoglobulin G (IgG)-mediated diseases and oral Factor D inhibitors, as well as early-stage work in conditions like light chain (AL) amyloidosis.
Corporate announcements, including the definitive agreement for AstraZeneca to acquire Alexion, add another dimension to the news landscape. Readers following ALXN news can expect coverage of clinical trial readouts, regulatory decisions, collaborations, scientific presentations and transaction-related updates. This mix of medical, scientific and corporate information helps market participants understand how Alexion’s rare disease portfolio and pipeline are evolving over time.
Alexion Pharmaceuticals (NASDAQ:ALXN) will present six abstracts at the 62nd Annual Meeting of the American Society of Hematology from December 5 to 8, 2020. Key findings include a Phase 3 analysis showing ULTOMIRIS® (ravulizumab-cwvz) is safe and effective for patients over 65 with paroxysmal nocturnal hemoglobinuria (PNH). Data will also cover the use of ULTOMIRIS with immunosuppressive therapy and highlight transfusion avoidance in PNH patients. Additionally, an analysis of aHUS patients underscores challenges in diagnosis and long-term disease persistence in untreated individuals.
Alexion Pharmaceuticals reported third-quarter 2020 revenues of $1,588.7 million, marking a 26% increase from 2019, despite a 2% negative impact from foreign currency. GAAP diluted EPS rose to $2.62, while non-GAAP diluted EPS increased 16% to $3.24. Notable product sales included SOLIRIS at $1,042.3 million and ULTOMIRIS at $289.3 million, a 222% rise. The company increased its full-year revenue guidance to $5,900-$5,950 million and provided updates on ongoing clinical trials and strategic initiatives amid COVID-19 challenges.
Alexion Pharmaceuticals (Nasdaq: ALXN) will announce its third-quarter financial results for the period ending September 30, 2020, on October 29, 2020, before the US markets open. Following the announcement, a conference call will be held from 8:00-9:00 a.m. ET where management will discuss the results. Participants can join the call by dialing (866) 762-3111 for the USA or (210) 874-7712 for international calls, using conference ID 6582445. The audio webcast will be available on the Investor page of ir.alexion.com, with an archived version accessible later.
Alexion Pharmaceuticals announced FDA approval for ULTOMIRIS® (ravulizumab-cwvz) 100 mg/mL for adults with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). This new formulation reduces average annual infusion times by approximately 60% compared to the 10 mg/mL version, allowing most patients to spend six hours or less annually receiving treatment. With a focus on improving patient care, Alexion plans to transition from ULTOMIRIS 10 mg/mL to 100 mg/mL swiftly and seeks additional regulatory approvals in the EU and Japan.
Alexion Pharmaceuticals (NASDAQ:ALXN) will present four abstracts at the American Society of Nephrology’s Kidney Week 2020, occurring virtually from October 22-25. The data will focus on ULTOMIRIS® (ravulizumab-cwvz) for treating pediatric patients with atypical hemolytic uremic syndrome (aHUS). Results indicate a 50% improvement in hematologic and renal outcomes in 94% of pediatric patients without previous complement inhibitor treatment. Additional findings include a switch study from SOLIRIS® (eculizumab) to ULTOMIRIS showing continued efficacy and reduced dosing frequency. The abstracts are available on the ASN website.
Alexion Pharmaceuticals (NASDAQ: ALXN) continues to advance its LEAD-EXPAND-DIVERSIFY strategy, showcasing its robust pipeline during a Virtual Investor Day. The company aims for a 2025 revenue target of $9 to $10 billion and plans to raise 2020 full-year revenue guidance by over $200 million. Key highlights include over 20 development programs, a commitment to return at least $3 billion to shareholders via stock buybacks, and ambitious plans for product launches and market expansion, particularly in rare disease treatment.